Literature DB >> 17700167

Inactivation of T-cell receptor-mediated integrin activation prolongs allograft survival in ADAP-deficient mice.

Jiong Tian1, Oliver Pabst, Dorothee Römermann, Susanne Skubich, Reinhold Förster, Jan Beckmann, Jiang-Hua Chen, Matthias W Hoffmann.   

Abstract

BACKGROUND: Signaling through the T cell receptor (TCR) leads to profound changes in the function and properties of T cells, including integrin activation. Adhesion and degranulation promoting adapter protein (ADAP) is an adapter protein linking T cell receptor stimulation to integrin activation. We aim to clarify how disruption of TCR-mediated integrin activation affects alloreactive immune responses.
METHODS: In vitro T cell proliferation and the cytokine production was determined. In vivo cytotoxic T lymphocyte (CTL) activity was measured as well. Allogenic skin and heart transplantation was used to test the in vivo role of ADAP in alloimmune responses. Histology and flow cytometry was applied to analyze the graft infiltrating lymphocytes.
RESULTS: Upon stimulation with allogenic dendritic cells ADAP-deficient T cells displayed impaired proliferative responses compared to wild type (WT) T cells. This was accompanied by significantly decreased production of the cytokine interleukin-2. In contrast, the in vivo CTL activity in ADAP-deficient mice was comparable to that of WT mice. Consistently, we observed a prolongation of fully major histocompatibility complex (MHC)-mismatched heart transplants in ADAP deficient mice. Protection of allogenic heart grafts in ADAP-deficient mice was accompanied by a decrease in the infiltration, proliferation and activation of T cells in the allograft. However, no effect was observed after fully MHC-mismatched skin transplantation.
CONCLUSIONS: We have shown that although ADAP is dispensable for the rejection of allografts, ADAP function plays an important role for the efficacy of graft rejection. ADAP's main function appears to affect the induction phase of the immune response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17700167     DOI: 10.1097/01.tp.0000269724.06142.92

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  Role of T cell-nuclear factor κB in transplantation.

Authors:  Luciana L Molinero; Maria-Luisa Alegre
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

2.  Distinct regulation of integrin-dependent T cell conjugate formation and NF-kappa B activation by the adapter protein ADAP.

Authors:  Brandon J Burbach; Rupa Srivastava; Ricardo B Medeiros; William E O'Gorman; Erik J Peterson; Yoji Shimizu
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

3.  ADAP interactions with talin and kindlin promote platelet integrin αIIbβ3 activation and stable fibrinogen binding.

Authors:  Ana Kasirer-Friede; Jian Kang; Bryan Kahner; Feng Ye; Mark H Ginsberg; Sanford J Shattil
Journal:  Blood       Date:  2014-02-12       Impact factor: 22.113

4.  Adhesion- and Degranulation-Promoting Adapter Protein Promotes CD8 T Cell Differentiation and Resident Memory Formation and Function during an Acute Infection.

Authors:  Jessica K Fiege; Lalit K Beura; Brandon J Burbach; Yoji Shimizu
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

5.  The adapter protein ADAP is required for selected dendritic cell functions.

Authors:  Mauro Togni; Swen Engelmann; Dirk Reinhold; Burkhart Schraven; Annegret Reinhold
Journal:  Cell Commun Signal       Date:  2012-06-06       Impact factor: 5.712

Review 6.  Memory T Cell Migration.

Authors:  Qianqian Zhang; Fadi G Lakkis
Journal:  Front Immunol       Date:  2015-10-02       Impact factor: 7.561

Review 7.  Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy.

Authors:  Kamalakannan Rajasekaran; Matthew J Riese; Sridhar Rao; Li Wang; Monica S Thakar; Charles L Sentman; Subramaniam Malarkannan
Journal:  Front Immunol       Date:  2016-05-12       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.